+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Patient-Derived Xenograft/PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

  • PDF Icon

    Report

  • 237 Pages
  • August 2023
  • Region: Global
  • Markets and Markets
  • ID: 5315029

The patient-derived xenografts/ PDX model market is projected to reach USD 687 million by 2028 from USD 366 million in 2023, at a CAGR of 13.4% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models are expected to restrain market growth to a certain extent.

The patient-derived xenografts/ PDX models market has been segmented based on type, implantation method, tumor type, application, end-user, and region. 

By type, the mouse model segment accounted for the largest share of the patient-derived xenografts/ PDX models market.

Based on type, the patient-derived xenografts/ PDX models market is categorized into mouse model and rat model. The mouse model segment is the largest and fastest-growing segment in the market in 2023, owing to ease of manipulation and procurement, and the minimum requirement for keeping them under observation compared to rats in the facilities has led to a higher growth rate for products in the patient-derived xenografts/ PDX models market.

By implantation method, subcutaneous implantation segment accounted for the largest share in the patient-derived xenografts/ PDX models market.

Based on implantation method, the market is segmented into subcutaneous implantation, orthotopic implantation, and other implantation methods (heterotopic implantation, intraocular implantation, and under the renal capsule). In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. Subcutaneous implantation involves implanting patient-derived tumor tissue under the skin of a host animal (often a mouse). This method is relatively simple and minimally invasive compared to other implantation methods, making it a practical choice for researchers.

North America: the largest share of the patient-derived xenografts/ PDX models market.

North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The region possesses a highly developed and robust biopharmaceutical industry, with advanced research and clinical infrastructure. This environment facilitates efficient collaboration between academia, research institutions, and pharmaceutical companies, enabling the effective utilization and adoption of PDX models.

Secondly, North America's regulatory framework supports the integration of innovative technologies, including PDX models, in preclinical and clinical research. The stringent regulatory standards ensure that PDX models are validated and applicable for drug development processes, thereby bolstering investor and industry confidence.

Moreover, the APAC region offers lucrative growth potential for the PDX models market. This region benefits from a robust healthcare infrastructure, a burgeoning biopharmaceutical industry, and a large patient population, fostering an ideal setting for PDX model utilization.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 63% and Demand Side- 37%
  • By Designation: Executives - 45%, Research Scientists- 30%, and Managers - 25%
  • By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America - 10%, and Middle East Africa- 5%

Prominent Players

  • JSR Corporation (Japan)
  • Wuxi Apptec (China)
  • The Jackson Laboratory (US)
  • Charles River Laboratories International, Inc. (US)
  • Taconic Biosciences, Inc. (US)
  • Oncodesign Precision Medicine (France)
  • Inotiv, Inc. (US)
  • Pharmatest Services (Finland)
  • Hera BioLabs (US)
  • EPO Berlin-Buch GmbH (Germany)
  • Xentech (France)
  • Urosphere (France)
  • Altogen Labs (US)
  • Abnova Corporation (US)
  • Genesis Biotechnology Group (US)
  • Biocytogen Pharmaceuticals Co., Ltd. (China)
  • Creative Animodel (US)
  • BioDuro-Sundia (US)
  • Aragen Life Sciences (India)
  • Shanghai LIDE Biotech Co., Ltd. (China)
  • Certis Oncology Solutions (US)
  • InnoSer (Netherlands)
  • IVRS AB (Sweden)
  • Beijing IDMO Co. Ltd. (China)
  • Shanghai Chempartner Co. Ltd. (China)

Research Coverage:

This report provides a detailed picture of the patient-derived xenografts/ PDX models market. It aims to estimate the size and future growth potential of the market across different segments, such as type, implantation method, tumor type, application, and end-user, and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall patient-derived xenografts/ PDX models market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX technology, and rising investments for cancer research), restraints (FDA’s announcement to discontinue animal models for clinical trials), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the growth of the patient-derived xenografts/PDX models market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the patient-derived xenografts/ PDX models market. 
  • Market Development: Comprehensive information about lucrative markets- the report analyses the patient-derived xenografts/ PDX models market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the patient-derived xenografts/ PDX models market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like JSR Corporation (Japan), The Jackson Laboratory (US), and Charles River Laboratories International, Inc. (US), among others, in the patient-derived xenografts/ PDX models market strategies. The report also helps stakeholders understand the pulse of the patient-derived xenografts/ PDX models market and provides them with information on key market drivers, restraints, challenges, and opportunities.

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered in the Report
1.4 Currency
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.2 Primary Data
Figure 2 Primary Sources
Figure 3 PDX Model Market: Breakdown of Primaries
2.1.2.1 Key Industry Insights
2.2 Market Size Estimation
Figure 4 Market Size Estimation: Approach 1 - Revenue Share Analysis, 2020
Figure 5 Average Market Size Estimation, 2020
Figure 6 Market: CAGR Projections, 2021-2026
Figure 7 Market: Growth Analysis of Drivers, Restraints, Opportunities, and Challenges
2.3 Market Breakdown and Data Triangulation
Figure 8 Data Triangulation Methodology
2.4 Research Assumptions
2.5 Risk Analysis

3 Executive Summary
Figure 9 PDX Model Market, by Type, 2021 Vs. 2026 (USD Million)
Figure 10 Market, by Tumor Type, 2021 Vs. 2026 (USD Million)
Figure 11 Market, by Application, 2021 Vs. 2026 (USD Million)
Figure 12 Market, by End-user, 2021 Vs. 2026 (USD Million)
Figure 13 Market: Geographic Snapshot

4 Premium Insights
4.1 PDX Model Market Overview
Figure 14 Increasing Support for Cancer Research from Public and Private Sectors and Growing Demand for Precision Medicine are Key Growth Drivers
4.2 North America: Market, Market Share (2020)
Figure 15 Mice Models Commanded the Largest Share of the North American Market in 2020
4.3 Market Share, by End-user (2020)
Figure 16 Pharmaceutical & Biotechnology Companies Commanded the Largest Share of the Market in 2020
4.4 Market: Geographic Growth Opportunities
Figure 17 China to Witness the Highest Growth in the Market During the Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 18 PDX Model Market: Drivers, Restraints, Opportunities, and Challenges
Table 1 PDX Model Industry: Impact Analysis
5.2.1 Drivers
5.2.1.1 Growing Demand for Personalized Medicine
5.2.1.2 Continuous Support for Cancer Research from the Public & Private Sectors
5.2.1.3 Rising Pharma R&D
5.2.2 Restraints
5.2.2.1 High Cost of Personalized PDX Models
5.2.2.2 Stringent Guidelines for the Use of Animal Models in Cancer Research
5.2.3 Opportunities
5.2.3.1 Rising Demand for Humanized PDX Models
5.2.4 Challenges
5.2.4.1 Limitations of PDX Models
5.3 Impact of the COVID-19 Outbreak on the Growth of the Market
5.4 Technological Analysis
5.5 Pricing Analysis
5.6 Value Chain Analysis
Figure 19 Value Chain Analysis of Market: R&D and Manufacturing Phases Add Maximum Value
Figure 20 Value Chain: Creation of PDX Models - Maximum Value is Added During the Implantations of Tumor Cells in Immunodeficient Mice or Rats
5.7 Ecosystem Analysis of the Market
Figure 21 Ecosystem Analysis of the Market
Table 2 Supply Chain Ecosystem
5.8 Porter's Five Forces Analysis
Table 3 Market: Porter's Five Forces Analysis
5.8.1 Threat of New Entrants
5.8.2 Threat of Substitutes
5.8.3 Bargaining Power of Buyers
5.8.4 Bargaining Power of Suppliers
5.8.5 Intensity of Competitive Rivalry
5.9 Regulatory Analysis
5.9.1 North America
5.9.2 Europe
5.9.3 Asia-Pacific
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.3.4 Australia
5.9.4 Latin America
5.9.5 Middle East & Africa
5.10 Patent Analysis
Figure 22 Patents Granted for PDX Models, January 2010-December 2020

6 PDX Model Market, by Type
6.1 Introduction
Table 4 PDX Model Industry, by Type, 2019-2026 (USD Million)
6.2 Mice Models
6.2.1 Ease of Procurement and Wide Availability of Mice Models Drive the Growth of this Segment
Table 5 PDX Mice Models Market, by Region, 2019-2026 (USD Million)
Table 6 North America: PDX Mice Models Market, by Country, 2019-2026 (USD Million)
Table 7 Europe: PDX Mice Models Market, by Country, 2019-2026 (USD Million)
Table 8 Asia-Pacific: PDX Mice Models Market, by Country, 2019-2026 (USD Million)
6.3 Rat Models
6.3.1 Factors Such as Easier Surgical Manipulation and Larger Tumor Size Will Support Use of Rat Models
Table 9 PDX Rat Models Market, by Region, 2019-2026 (USD Million)
Table 10 North America: PDX Rat Models Market, by Country, 2019-2026 (USD Million)
Table 11 Europe: PDX Rat Models Market, by Country, 2019-2026 (USD Million)
Table 12 Asia-Pacific: PDX Rat Models Market, by Country, 2019-2026 (USD Million)

7 PDX Model Market, by Tumor Type
7.1 Introduction
Table 13 PDX Model Industry, by Tumor Type, 2019-2026 (USD Million)
7.2 Gastrointestinal Tumor Models
7.2.1 Newly Developed Gastrointestinal Tumor Models Mimic the Tumor Better Than Previous Models
Table 14 Gastrointestinal Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 15 North America: Gastrointestinal Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 16 Europe: Gastrointestinal Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 17 Asia-Pacific: Gastrointestinal Tumor Models Market, by Country, 2019-2026 (USD Million)
7.3 Gynecological Tumor Models
7.3.1 High Incidence of Target Cancers Has Driven Demand for Tumor Models
Table 18 Gynecological Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 19 North America: Gynecological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 20 Europe: Gynecological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 21 Asia-Pacific: Gynecological Tumor Models Market, by Country, 2019-2026 (USD Million)
7.4 Respiratory Tumor Models
7.4.1 Rising Prevalence of Lung Cancer to Drive Market Growth
Table 22 Respiratory Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 23 North America: Respiratory Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 24 Europe: Respiratory Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 25 Asia-Pacific: Respiratory Tumor Models Market, by Country, 2019-2026 (USD Million)
7.5 Urological Tumor Models
7.5.1 Companies are Focusing on Expanding Their Portfolio for Urological Cancers
Table 26 Urological Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 27 North America: Urological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 28 Europe: Urological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 29 Asia-Pacific: Urological Tumor Models Market, by Country, 2019-2026 (USD Million)
7.6 Hematological Tumor Models
7.6.1 New Strains Such as Nsg and Nog Have Increased the Life Span of Hematological Tumor Models
Table 30 Hematological Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 31 North America: Hematological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 32 Europe: Hematological Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 33 Asia-Pacific: Hematological Tumor Models Market, by Country, 2019-2026 (USD Million)
7.7 Other Tumor Models
Table 34 Other Tumor Models Market, by Region, 2019-2026 (USD Million)
Table 35 North America: Other Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 36 Europe: Other Tumor Models Market, by Country, 2019-2026 (USD Million)
Table 37 Asia-Pacific: Other Tumor Models Market, by Country, 2019-2026 (USD Million)

8 PDX Model Market, by Application
8.1 Introduction
Table 38 PDX Model Industry, by Application, 2021-2026 (USD Million)
8.2 Preclinical Drug Development
8.2.1 Rise in Number of Clinical Trials Will Drive the Growth of this Segment
Table 39 Market for Preclinical Drug Development, by Region, 2019-2026 (USD Million)
Table 40 North America: Market for Preclinical Drug Development, by Country, 2019-2026 (USD Million)
Table 41 Europe: Market for Preclinical Drug Development, by Country, 2019-2026 (USD Million)
Table 42 Asia-Pacific: Market for Preclinical Drug Development, by Country, 2019-2026 (USD Million)
8.3 Biomarker Analysis
8.3.1 Growing Interest in Precision Medicine Will Contribute to the Demand for PDX Models for Biomarker Analysis
Table 43 Market for Biomarker Analysis, by Region, 2019-2026 (USD Million)
Table 44 North America: Market for Biomarker Analysis, by Country, 2019-2026 (USD Million)
Table 45 Europe: Market for Biomarker Analysis, by Country, 2019-2026 (USD Million)
Table 46 Asia-Pacific: Market for Biomarker Analysis, by Country, 2019-2026 (USD Million)
8.4 Basic Cancer Research
8.4.1 Rising Funding for Cancer Research Will Drive Market Growth in this Segment
Table 47 Market for Basic Cancer Research, by Region, 2019-2026 (USD Million)
Table 48 North America: Market for Basic Cancer Research, by Country, 2019-2026 (USD Million)
Table 49 Europe: Market for Basic Cancer Research, by Country, 2019-2026 (USD Million)
Table 50 Asia-Pacific: Market for Basic Cancer Research, by Country, 2019-2026 (USD Million)

9 PDX Model Market, by End-user
9.1 Introduction
Table 51 PDX Model Industry, by End-user, 2019-2026 (USD Million)
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Rising Collaboration Between Pharma & Biotech Companies for Developing Cancer Therapeutics
Table 52 Market for Pharmaceutical & Biotechnology Companies, by Region, 2019-2026 (USD Million)
Table 53 North America: Market for Pharmaceutical and Biotechnology Companies, by Country, 2019-2026 (USD Million)
Table 54 Europe: Market for Pharmaceutical and Biotechnology Companies, by Country, 2019-2026 (USD Million)
Table 55 Asia-Pacific: Market for Pharmaceutical and Biotechnology Companies, by Country, 2019-2026 (USD Million)
9.3 Contract Research Organizations
9.3.1 Rising Outsourcing of Drug Discovery Services Will Drive Market Growth
Table 56 Market for Contract Research Organizations, by Region, 2019-2026 (USD Million)
Table 57 North America: Market for Contract Research Organizations, by Country, 2019-2026 (USD Million)
Table 58 Europe: Market for Contract Research Organizations, by Country, 2019-2026 (USD Million)
Table 59 Asia-Pacific: Market for Contract Research Organizations, by Country, 2019-2026 (USD Million)
9.4 Academic & Research Institutions
9.4.1 Increase in Government Life Sciences R&D Expenditure Will Contribute to the Growth of this Segment
Table 60 Market for Academic & Research Institutions, by Region, 2019-2026 (USD Million)
Table 61 North America: Market for Academic & Research Institutions, by Country, 2019-2026 (USD Million)
Table 62 Europe: Market for Academic & Research Institutions, by Country, 2019-2026 (USD Million)
Table 63 Asia-Pacific: Market for Academic & Research Institutions, by Country, 2019-2026 (USD Million)

10 PDX Model Market, by Region
10.2 North America
Table 64 PDX Model Industry, by Region, 2019-2026 (USD Million)
10.2 North America
Figure 23 North America: PDX Model Market Snapshot
Table 65 North America: Market, by Country, 2019-2026 (USD Million)
Table 66 North America: Market, by Type, 2019-2026 (USD Million)
Table 67 North America: Market, by Tumor Type, 2019-2026 (USD Million)
Table 68 North America: Market, by Application, 2019-2026 (USD Million)
Table 69 North America: Market, by End-user, 2019-2026 (USD Million)
10.2.1 US
10.2.1.1 Growing Focus on Cancer Research in the Us Will Drive Market Growth
Table 70 US: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 71 US: Market, by Tumor Type, 2019-2026 (USD Million)
Table 72 US: Market, by Application, 2019-2026 (USD Million)
Table 73 US: Market, by End-user, 2019-2026 (USD Million)
10.2.2 Canada
10.2.2.1 Growth in Canada Can be Attributed to Rising Funding for Stem Cell Research in the Country
Table 74 Canada: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 75 Canada: Market, by Tumor Type, 2019-2026 (USD Million)
Table 76 Canada: Market, by Application, 2019-2026 (USD Million)
Table 77 Canada: Market, by End-user, 2019-2026 (USD Million)
10.3 Europe
Table 78 Europe: PDX Model Market, by Country/Region, 2019-2026 (USD Million)
Table 79 Europe: Market, by Type, 2019-2026 (USD Million)
Table 80 Europe: Market, by Tumor Type, 2019-2026 (USD Million)
Table 81 Europe: Market, by Application, 2019-2026 (USD Million)
Table 82 Europe: PDX Model Industry, by End-user, 2019-2026 (USD Million)
10.3.1 Germany
10.3.1.1 Government Funding for Life Science R&D and Basic Cancer Research Will Drive Market Growth
Table 83 Germany: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 84 Germany: Market, by Tumor Type, 2019-2026 (USD Million)
Table 85 Germany: Market, by Application, 2019-2026 (USD Million)
Table 86 Germany: Market, by End-user, 2019-2026 (USD Million)
10.3.2 UK
10.3.2.1 The Rising Incidence of Cancer Cases Will Lead to an Increase in Cancer Research, Which Will Drive Market Growth
Table 87 UK: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 88 UK: Market, by Tumor Type, 2019-2026 (USD Million)
Table 89 UK: Market, by Application, 2019-2026 (USD Million)
Table 90 UK: Market, by End-user, 2019-2026 (USD Million)
10.3.3 France
10.3.3.1 Increasing Government Funding for Cancer Research
Table 91 France: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 92 France: Market, by Tumor Type, 2019-2026 (USD Million)
Table 93 France: Market, by Application, 2019-2026 (USD Million)
Table 94 France: Market, by End-user, 2019-2026 (USD Million)
10.3.4 Roe
Table 95 Roe: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 96 Roe: Market, by Tumor Type, 2019-2026 (USD Million)
Table 97 Roe: Market, by Application, 2019-2026 (USD Million)
Table 98 Roe: PDX Model Industry, by End-user, 2019-2026 (USD Million)
10.4 Asia-Pacific
Figure 24 Asia-Pacific: PDX Model Market Snapshot
Table 99 Asia-Pacific: Market, by Country, 2019-2026 (USD Million)
Table 100 Asia-Pacific: Market, by Type, 2019-2026 (USD Million)
Table 101 Asia-Pacific: Market, by Tumor Type, 2019-2026 (USD Million)
Table 102 Asia-Pacific: Market, by Application, 2019-2026 (USD Million)
Table 103 Asia-Pacific: Market, by End-user, 2019-2026 (USD Million)
10.4.1 China
10.4.1.1 The Growing Pharmaceutical Industry and Rising Number of Cros in the Country Will Drive Market Growth
Table 104 China: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 105 China: Market, by Tumor Type, 2019-2026 (USD Million)
Table 106 China: Market, by Application, 2019-2026 (USD Million)
Table 107 China: Market, by End-user, 2019-2026 (USD Million)
10.4.2 Japan
10.4.2.1 Research Collaborations and Growing Geriatric Population - Key Growth Drivers in Japan
Table 108 Japan: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 109 Japan: Market, by Tumor Type, 2019-2026 (USD Million)
Table 110 Japan: Market, by Application, 2019-2026 (USD Million)
Table 111 Japan: Market, by End-user, 2019-2026 (USD Million)
10.4.3 Rest of Asia-Pacific
Table 112 Roapac: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 113 Roapac: Market, by Tumor Type, 2019-2026 (USD Million)
Table 114 Roapac: Market, by Application, 2019-2026 (USD Million)
Table 115 Roapac: PDX Model Industry, by End-user, 2019-2026 (USD Million)
10.5 Latin America
10.5.1 Rising Pharmaceutical R&D Expenditure in the Region Will Drive the Growth of the Market
Table 116 Latin America: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 117 Latin America: Market, by Tumor Type, 2019-2026 (USD Million)
Table 118 Latin America: Market, by Application, 2019-2026 (USD Million)
Table 119 Latin America: Market, by End-user, 2019-2026 (USD Million)
10.6 Middle East & Africa
10.6.1 Market Growth Driven by Changing Demographics and Favorable Policies for Pharma R&D
Table 120 Middle East and Africa: PDX Model Market, by Type, 2019-2026 (USD Million)
Table 121 Middle East and Africa: Market, by Tumor Type, 2019-2026 (USD Million)
Table 122 Middle East and Africa: Market, by Application, 2019-2026 (USD Million)
Table 123 Middle East and Africa: Market, by End-user, 2019-2026 (USD Million)

11 Competitive Landscape
11.1 Overview
11.2 Market Evaluation Framework
Table 124 Market Evaluation Framework: Partnerships, Agreements, Joint Ventures, and Collaborations - The Major Strategies Adopted by Players
11.3 Market Share Analysis
Figure 25 PDX Model Market Share Analysis, by Key Player, 2020
11.4 Revenue Share Analysis of Top Market Players
Figure 26 Top Market Players Dominate the PDX Model Industry
11.5 Company Evaluation Quadrant
11.5.1 Stars
11.5.2 Emerging Leaders
11.5.3 Pervasive
11.5.4 Emerging Companies
Figure 27 Market: Company Evaluation Quadrant, 2020
11.6 Company Evaluation Quadrant: Start-Ups/Smes
11.6.1 Progressive Companies
11.6.2 Starting Blocks
11.6.3 Responsive Companies
11.6.4 Dynamic Companies
Figure 28 Market: Company Evaluation Quadrant for Start-Ups/Smes, 2020
11.7 Company Product Footprint
Table 125 Product Portfolio Analysis: Market (2020)
11.8 Company Geographic Footprint
Table 126 Geographic Revenue Mix: Market (2020)
11.9 Competitive Scenario
11.9.1 Market: Product & Service Launches, January 2018-February 2021
11.9.2 PDX Model Industry: Deals, January 2019-February 2021
11.9.3 PDX Model Market: Other Developments, January 2018-February 2021

12 Company Profiles
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Analyst's View)*
12.1 Key Market Players
12.1.1 Jsr Corporation
Figure 29 Jsr Corporation: Company Snapshot (2019)
12.1.2 Wuxi Apptec
Figure 30 Wuxi Apptec: Company Snapshot (2020)
12.1.3 The Jackson Laboratory
Figure 31 The Jackson Laboratory: Company Snapshot (2019)
12.1.4 Charles River Laboratories
Figure 32 Charles River Laboratories: Company Snapshot (2020)
12.1.5 Champions Oncology
Figure 33 Champions Oncology: Company Snapshot (2020)
12.1.6 Oncodesign
Figure 34 Oncodesign: Company Snapshot (2020)
12.1.7 Envigo
12.1.8 Pharmatest Services
12.1.9 Hera Biolabs
12.1.10 Epo Berlin-Buch GmbH
12.1.11 Xentech
12.1.12 Urosphere
12.2 Other Players
12.2.1 Abnova Corporation
12.2.2 Genesis Biotechnology Group
12.2.3 Explora Biolabs
12.2.4 Biocytogen
12.2.5 Living Tumor Laboratory
12.2.6 Bioduro
12.2.7 Aragen Life Sciences W.E.F
12.2.8 Shanghai Lide Biotech
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, Analyst's View Might Not be Captured in Case of Unlisted Companies.

13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store: The Subscription Portal
13.3 Available Customizations

Companies Mentioned

  • Abnova Corporation
  • Aragen Life Sciences W.E.F
  • Biocytogen
  • Bioduro
  • Champions Oncology
  • Charles River Laboratories
  • Envigo
  • EPO Berlin-Buch GmbH
  • Explora Biolabs
  • Genesis Biotechnology Group
  • Hera Biolabs
  • JSR Corporation
  • Living Tumor Laboratory
  • Oncodesign
  • Pharmatest Services
  • Shanghai Lide Biotech
  • The Jackson Laboratory
  • Urosphere
  • WuXi AppTec
  • Xentech

Table Information